Silk Road Medical Inc. (SILK) Misses Q1 EPS by 1c, Revenues Beat

Silk Road Medical Inc. (NASDAQ: SILK) reported Q1 EPS of ($0.32), $0.01 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $18.9 million versus the consensus estimate of $17.33 million.

“As we continue through these challenging times, we are confident in the foundational strength of our business and the culture that we have built at Silk Road Medical,” said Erica Rogers, Chief Executive Officer. “While our short-term priorities have temporarily shifted in light of the COVID-19 outbreak, we remain undeterred in our longstanding pursuit to change the standard of care. We have proven that TCAR is a more efficient, safer procedure for many patients and we are committed to improving the lives of carotid artery disease patients with this technology.”

2020 Financial Guidance

Silk Road Medical withdrew its previously announced annual guidance for 2020 on April 6, 2020. Given the uncertain scope and duration of the COVID-19 pandemic, the company remains unable to accurately estimate the impact of the pandemic on its operations and financial results.

For earnings history and earnings-related data on Silk Road Medical Inc. (SILK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c